Literature DB >> 25672905

Persistence of Sulfadoxine-Pyrimethamine Resistance Despite Reduction of Drug Pressure in Malawi.

Elena Artimovich1, Kristan Schneider2, Terrie E Taylor3, James G Kublin4, Fraction K Dzinjalamala5, Ananias A Escalante6, Christopher V Plowe1, Miriam K Laufer1, Shannon Takala-Harrison1.   

Abstract

BACKGROUND: In 2007, Malawi replaced sulfadoxine-pyrimethamine (SP) with an artemisinin-based combination therapy as the first-line treatment for uncomplicated Plasmodium falciparum malaria in response to failing SP efficacy. Here we estimate the effect of reduced SP pressure on the prevalence of SP-resistant parasites and the characteristics of the associated selective sweeps flanking the resistance loci.
METHODS: Samples obtained from individuals with clinical malaria during a period of high SP use (1999-2001), a transitional period (2007-2008), and a period of low SP use (2012) were genotyped for resistance markers at pfdhfr-ts codons 51, 59, and 108 and pfdhps codons 437, 540, and 581. Expected heterozygosity was estimated to evaluate the genetic diversity flanking pfdhfr-ts and pfdhps.
RESULTS: An increase in the prevalence of the resistance haplotypes DHFR 51I/59R/108N and DHPS 437G/540E occurred under sustained drug pressure, with no change in haplotype prevalence 5 years after reduction in SP pressure. The DHPS 437G/540E/581G haplotype was observed in 2007 and increased in prevalence during a period of reduced SP pressure. Changes to the sweep characteristics flanking pfdhfr-ts and pfdhps were minimal.
CONCLUSIONS: In contrast to the rapid and complete return of chloroquine-susceptible falciparum malaria after chloroquine was withdrawn from Malawi, a reemergence of SP efficacy is unlikely in the near future.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  DHFR; DHPS; malaria; pyrosequencing; resistance; selective sweeps; sulfadoxine-pyrimethamine

Mesh:

Substances:

Year:  2015        PMID: 25672905      PMCID: PMC4539899          DOI: 10.1093/infdis/jiv078

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  33 in total

1.  Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria.

Authors:  James G Kublin; Fraction K Dzinjalamala; Deborah D Kamwendo; Elissa M Malkin; Joseph F Cortese; Lisa M Martino; Rabia A G Mukadam; Stephen J Rogerson; Andres G Lescano; Malcolm E Molyneux; Peter A Winstanley; Phillips Chimpeni; Terrie E Taylor; Christopher V Plowe
Journal:  J Infect Dis       Date:  2002-01-17       Impact factor: 5.226

2.  Basis for antifolate action and resistance in malaria.

Authors:  Yongyuth Yuthavong
Journal:  Microbes Infect       Date:  2002-02       Impact factor: 2.700

3.  Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine.

Authors:  J K Iyer; W K Milhous; J F Cortese; J G Kublin; C V Plowe
Journal:  Lancet       Date:  2001-09-29       Impact factor: 79.321

4.  Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum.

Authors:  John C Wootton; Xiaorong Feng; Michael T Ferdig; Roland A Cooper; Jianbing Mu; Dror I Baruch; Alan J Magill; Xin-Zhuan Su
Journal:  Nature       Date:  2002-07-18       Impact factor: 49.962

5.  Temporal trends of sulphadoxine-pyrimethamine (SP) drug-resistance molecular markers in Plasmodium falciparum parasites from pregnant women in western Kenya.

Authors:  Nnaemeka C Iriemenam; Monica Shah; Wangeci Gatei; Anna M van Eijk; John Ayisi; Simon Kariuki; Jodi Vanden Eng; Simon O Owino; Ashima A Lal; Yusuf O Omosun; Kephas Otieno; Meghna Desai; Feiko O ter Kuile; Bernard Nahlen; Julie Moore; Mary J Hamel; Peter Ouma; Laurence Slutsker; Ya Ping Shi
Journal:  Malar J       Date:  2012-07-04       Impact factor: 2.979

6.  A likelihood approach to estimate the number of co-infections.

Authors:  Kristan A Schneider; Ananias A Escalante
Journal:  PLoS One       Date:  2014-07-02       Impact factor: 3.240

7.  Estimation of malaria haplotype and genotype frequencies: a statistical approach to overcome the challenge associated with multiclonal infections.

Authors:  Aimee R Taylor; Jennifer A Flegg; Samuel L Nsobya; Adoke Yeka; Moses R Kamya; Philip J Rosenthal; Grant Dorsey; Carol H Sibley; Philippe J Guerin; Chris C Holmes
Journal:  Malar J       Date:  2014-03-17       Impact factor: 2.979

8.  Sampling for microsatellite-based population genetic studies: 25 to 30 individuals per population is enough to accurately estimate allele frequencies.

Authors:  Marie L Hale; Theresa M Burg; Tammy E Steeves
Journal:  PLoS One       Date:  2012-09-12       Impact factor: 3.240

9.  A longitudinal trial comparing chloroquine as monotherapy or in combination with artesunate, azithromycin or atovaquone-proguanil to treat malaria.

Authors:  Miriam K Laufer; Phillip C Thesing; Fraction K Dzinjalamala; Osward M Nyirenda; Rhoda Masonga; Matthew B Laurens; Abbie Stokes-Riner; Terrie E Taylor; Christopher V Plowe
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

10.  Independent lineages of highly sulfadoxine-resistant Plasmodium falciparum haplotypes, eastern Africa.

Authors:  Steve M Taylor; Alejandro L Antonia; Whitney E Harrington; Morgan M Goheen; Victor Mwapasa; Ebbie Chaluluka; Michal Fried; Edward Kabyemela; Mwayi Madanitsa; Carole Khairallah; Linda Kalilani-Phiri; Antoinette K Tshefu; Stephen J Rogerson; Feiko O Ter Kuile; Patrick E Duffy; Steven R Meshnick
Journal:  Emerg Infect Dis       Date:  2014-07       Impact factor: 6.883

View more
  16 in total

1.  Multiple Single-Nucleotide Polymorphism Detection for Antimalarial Pyrimethamine Resistance via Allele-Specific PCR Coupled with Gold Nanoparticle-Based Lateral Flow Biosensor.

Authors:  Tingting Jiang; Yan Huang; Weijia Cheng; Yifei Sun; Wei Wei; Kai Wu; Chen Shen; Xiaolong Fu; Haifeng Dong; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

2.  Chloroquine as weekly chemoprophylaxis or intermittent treatment to prevent malaria in pregnancy in Malawi: a randomised controlled trial.

Authors:  Titus H Divala; Randy G Mungwira; Patricia M Mawindo; Osward M Nyirenda; Maxwell Kanjala; Masiye Ndaferankhande; Lufina E Tsirizani; Rhoda Masonga; Francis Muwalo; Sarah Boudová; Gail E Potter; Jessie Kennedy; Jaya Goswami; Blair J Wylie; Atis Muehlenbachs; Lughano Ndovie; Priscilla Mvula; Yamikani Mbilizi; Tamiwe Tomoka; Miriam K Laufer
Journal:  Lancet Infect Dis       Date:  2018-09-05       Impact factor: 25.071

Review 3.  Antimalarial drug resistance in Africa: key lessons for the future.

Authors:  Shannon Takala-Harrison; Miriam K Laufer
Journal:  Ann N Y Acad Sci       Date:  2015-04       Impact factor: 5.691

4.  High burden of malaria among Malawian adults on antiretroviral therapy after discontinuing prophylaxis.

Authors:  Randy G Mungwira; Matthew B Laurens; Wongani Nyangulu; Titus H Divala; Nginache Nampota-Nkomba; Andrea G Buchwald; Osward M Nyirenda; Edson Mwinjiwa; Maxwell Kanjala; Lufina Tsirizani Galileya; Dominique E Earland; Matthew Adams; Christopher V Plowe; Terrie E Taylor; Jane Mallewa; Joep J van Oosterhout; Miriam K Laufer
Journal:  AIDS       Date:  2022-07-15       Impact factor: 4.632

5.  The effect of local variation in malaria transmission on the prevalence of sulfadoxine-pyrimethamine resistant haplotypes and selective sweep characteristics in Malawi.

Authors:  Elena Artimovich; Atupele Kapito-Tembo; Paul Pensulo; Osward Nyirenda; Sarah Brown; Sudhaunshu Joshi; Terrie E Taylor; Don Mathanga; Ananias A Escalante; Miriam K Laufer; Shannon Takala-Harrison
Journal:  Malar J       Date:  2015-10-05       Impact factor: 2.979

6.  Characterizing the impact of sustained sulfadoxine/pyrimethamine use upon the Plasmodium falciparum population in Malawi.

Authors:  Matt Ravenhall; Ernest Diez Benavente; Mwapatsa Mipando; Anja T R Jensen; Colin J Sutherland; Cally Roper; Nuno Sepúlveda; Dominic P Kwiatkowski; Jacqui Montgomery; Kamija S Phiri; Anja Terlouw; Alister Craig; Susana Campino; Harold Ocholla; Taane G Clark
Journal:  Malar J       Date:  2016-11-29       Impact factor: 2.979

7.  Providing lipid-based nutrient supplement during pregnancy does not reduce the risk of maternal P falciparum parasitaemia and reproductive tract infections: a randomised controlled trial.

Authors:  Minyanga Nkhoma; Per Ashorn; Ulla Ashorn; Kathryn G Dewey; Austrida Gondwe; John Mbotwa; Stephen Rogerson; Steve M Taylor; Kenneth Maleta
Journal:  BMC Pregnancy Childbirth       Date:  2017-01-17       Impact factor: 3.007

Review 8.  Putting evolution in elimination: Winning our ongoing battle with evolving malaria mosquitoes and parasites.

Authors:  Silvie Huijben; Krijn P Paaijmans
Journal:  Evol Appl       Date:  2017-11-06       Impact factor: 5.183

9.  Prevalence of the dhfr and dhps Mutations among Pregnant Women in Rural Burkina Faso Five Years after the Introduction of Intermittent Preventive Treatment with Sulfadoxine-Pyrimethamine.

Authors:  Marc C Tahita; Halidou Tinto; Annette Erhart; Adama Kazienga; Robert Fitzhenry; Chantal VanOvermeir; Anna Rosanas-Urgell; Jean-Bosco Ouedraogo; Robert T Guiguemde; Jean-Pierre Van Geertruyden; Umberto D'Alessandro
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

10.  Scheduled Intermittent Screening with Rapid Diagnostic Tests and Treatment with Dihydroartemisinin-Piperaquine versus Intermittent Preventive Therapy with Sulfadoxine-Pyrimethamine for Malaria in Pregnancy in Malawi: An Open-Label Randomized Controlled Trial.

Authors:  Mwayiwawo Madanitsa; Linda Kalilani; Victor Mwapasa; Anna M van Eijk; Carole Khairallah; Doreen Ali; Cheryl Pace; James Smedley; Kyaw-Lay Thwai; Brandt Levitt; Duolao Wang; Arthur Kang'ombe; Brian Faragher; Steve M Taylor; Steve Meshnick; Feiko O Ter Kuile
Journal:  PLoS Med       Date:  2016-09-13       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.